Cancer Cell Patents (Class 424/155.1)
-
Publication number: 20100150935Abstract: The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the protein CXCR4 and thereby inhibiting tumour growth, in the preparation of a medicament intended for the treatment of cancer. The invention is also directed to a composition for the treatment of cancer, comprising, as active ingredient, at least one anti-CXCR4 antibody, or a functional fragment thereof, which is capable of binding to the protein CXCR4 and/or of inhibiting its angiogenic and/or proliferative activity. More especially, said antibodies consist of the antibody MAB173.Type: ApplicationFiled: April 18, 2008Publication date: June 17, 2010Applicant: PIERRE FABRE MEDICAMENTInventor: Christine Klinguer-Hamour
-
Patent number: 7736647Abstract: The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumor cells, especially metastatic cutaneous and uveal melanoma cells.Type: GrantFiled: June 15, 2005Date of Patent: June 15, 2010Assignees: Monoclonal Antibodies Therapeutics, Institut National de la Sante et de la Recherche Medicale (Inserm)Inventors: Laurence Boumsell, Armand Bensussan, Jean Kadouche
-
Patent number: 7736651Abstract: The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (>1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, including normal cells, that are targets for destruction, to achieve a therapeutic result. The alpha emitting constructs have high specific activity.Type: GrantFiled: November 24, 2000Date of Patent: June 15, 2010Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: David Scheinberg, Dangshe Ma, Michael R. McDevitt, George Sgouros
-
Publication number: 20100143359Abstract: The present invention relates to the treatment, diagnosis, and prophylaxis of cancer based on the expression of foxp3.Type: ApplicationFiled: November 27, 2007Publication date: June 10, 2010Applicant: Ludwig Institute for Cancer Research Ltd.Inventors: Lisa Michelle Ebert, Weisan Chen, Jonathan S. Cebon, Ian Davis
-
Publication number: 20100146650Abstract: The present invention relates to the use of a milled homogenate and/or a suspension and/or a cell lysate, stemming from a tumor resistant to at least one anti-tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen specifically expressed at the surface of said resistant tumor and being possibly involved in the resistance of said resistant tumor. More particularly, the present invention is directed to such antibodies obtained by applying the method, such as the antibodies 1A6, 1A9, 2E11, 3C11 and 3G7, as well as to their use for treating cancer.Type: ApplicationFiled: September 27, 2007Publication date: June 10, 2010Applicant: Pierre Fabre MedicamentInventors: Liliane Goetsch, Alexandra Jouhanneaud
-
Patent number: 7731963Abstract: The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.Type: GrantFiled: March 20, 2007Date of Patent: June 8, 2010Assignee: Biogen Idec MA Inc.Inventors: Jeffrey Browning, Linda Burkly, Aniela Jakubowski, Timothy Zheng
-
Patent number: 7727530Abstract: The present invention relates to a pharmaceutical composition comprising of proline or proline derivatives or their salts, esters, isomers, racemates, enantiomeres or prodrugs together with an anti-cancer ligand, preferably an antibody directed to a tumour antigen. The invention is also directed to the use of proline or proline derivatives or their salts, esters, isomers or prodrugs for the manufacture of a pharmaceutical composition for treating cancer and to a method of cancer treatment by administering said composition.Type: GrantFiled: June 8, 2005Date of Patent: June 1, 2010Inventor: Zoser B. Salama
-
Patent number: 7727525Abstract: The present invention provides anti-CD20 antibody fragments for use as in vivo imaging probes and as therapeutic moieties for the diagnosis and treatment of NHL.Type: GrantFiled: April 27, 2007Date of Patent: June 1, 2010Assignees: City of Hope, The Regents of the University of CaliforniaInventors: Anna M. Wu, Tove Olafsen, Andrew A. Raubitschek
-
Patent number: 7713526Abstract: The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt/Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the proliferation and survival of a subset of HNSCC may depend on the Wnt/Fzd pathway. Therefore, the Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.Type: GrantFiled: November 1, 2002Date of Patent: May 11, 2010Assignee: The Regents of the University of CaliforniaInventors: Chae-Seo Rhee, Malini Sen, Christina Wu, Lorenzo M. Leoni, Maripat Corr, Dennis A. Carson
-
Patent number: 7708994Abstract: The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNF?-inhibitor.Type: GrantFiled: May 24, 2006Date of Patent: May 4, 2010Assignee: Genentech, Inc.Inventor: Mark C. Benyunes
-
Patent number: 7709220Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.Type: GrantFiled: June 23, 2006Date of Patent: May 4, 2010Assignee: Biogen Idec MA Inc.Inventors: Christine M. Ambrose, Jeffrey S. Thompson
-
Publication number: 20100104578Abstract: The invention relates to methods of treating a neoplasm in an animal, in particular treating a neoplasm in a human, through the use of isolated nucleic acid sequence, including synthetic viral RNA and complementary DNA, derived from one or more Picornaviruses. The invention also relates to compositions of isolated nucleic acids derived from one or more Picornaviruses, and to the use of isolated nucleic acids derived from one or more Picornaviruses for the manufacture of a medicament for the treatment of neoplasms in a mammal.Type: ApplicationFiled: October 16, 2009Publication date: April 29, 2010Inventor: Darren Raymond Shafren
-
Publication number: 20100104577Abstract: This document provides methods and materials related to anti-A? antibodies. For example, anti-A? antibodies, methods for making anti-A? antibodies, and methods for using an anti-A? antibody to treat or prevent an amyloid condition (e.g., AD).Type: ApplicationFiled: October 10, 2007Publication date: April 29, 2010Inventors: Todd E. Golde, Pritam Das, Karen R. Jansen-West, Yona R. Levites
-
Patent number: 7700097Abstract: The instant invention describes methods of separating or preferentially synthesizing dimers which are linked via at least one interchain disulfide linkage from dimers which are not linked via at least one interchain disulfide linkage from a mixture comprising the two types of polypeptide dimers. These forms can be separated from each other using hydrophobic interaction chromatography. In addition, the invention pertains to connecting peptides that result in the preferential biosynthesis of dimers that are linked via at least one interchain disulfide linkage or that are not linked via at least one interchain disulfide linkage. The invention also pertains to compositions in which a majority of the dimers are linked via at least one interchain disulfide linkage or are not linked via at least one interchain disulfide linkage. The invention still further pertains to novel binding molecules, e.g., comprising connecting peptides of the invention.Type: GrantFiled: June 28, 2004Date of Patent: April 20, 2010Assignee: Biogen Idec MA Inc.Inventors: Gary R. Braslawsky, Scott Glaser, Tzung-Horng Yang, Jennifer Hopp, Paul Chinn
-
Patent number: 7691380Abstract: Disclosed are various compositions and methods for use in achieving specific blood coagulation. This is exemplified by the specific in vivo coagulation of tumor vasculature, causing tumor regression, through the site-specific delivery of a coagulant using a bispecific antibody.Type: GrantFiled: February 27, 2003Date of Patent: April 6, 2010Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Thomas S. Edgington
-
Patent number: 7691374Abstract: The present invention provides a method for enhancing the efficacy of chemotherapeutic agents for therapy of cancer including tumors and other angiogenesis-associated diseases such as rheumatoid arthritis. The method comprises the steps of administering to an individual in need of treatment, a combination of an anti-endoglin antibody and a chemotherapeutic agent. The anti-endoglin antibody and the chemotherapeutic agent may be administered sequentially or concurrently.Type: GrantFiled: August 25, 2006Date of Patent: April 6, 2010Assignee: Health Research, Inc.Inventor: Ben K. Seon
-
Patent number: 7691376Abstract: The present invention is directed to cell surface antigens found on myeloma cells and on ovarian cancer cells that are recognized by monoclonal antibodies, and antibody binding fragments thereof, as described. The monoclonal antibodies of the invention are capable of being used for therapeutic, screening, diagnostic and cell purification purposes. A representative and exemplified monoclonal antibody of the present invention recognizes and binds to an epitope common to a surface antigen that is expressed on multiple myeloma cells and to a surface antigen that is expressed on ovarian cancer cells. The function of this monoclonal antibody both in vivo and in vitro is demonstrated.Type: GrantFiled: May 24, 2007Date of Patent: April 6, 2010Assignee: ImmunoCellular Therapeutics, Ltd.Inventor: Cohava Gelber
-
Publication number: 20100074841Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.Type: ApplicationFiled: November 19, 2009Publication date: March 25, 2010Applicant: FACET BIOTECH CORPORATIONInventors: Debbie Law, Kurt C. Gish, Richard Murray, Patricia Culp
-
Patent number: 7674462Abstract: The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications.Type: GrantFiled: April 30, 2007Date of Patent: March 9, 2010Assignee: Biogen Idec MA Inc.Inventors: Michele Sanicola-Nadel, Kevin P. Williams, Susan Gail Schiffer, Paul Rayhorn
-
Patent number: 7670604Abstract: Disclosed are methods for treating or preventing a neoplastic or a multidrug resistant neoplasm in a subject using cell surface vimentin targeted therapeutic agents.Type: GrantFiled: July 1, 2005Date of Patent: March 2, 2010Assignee: Aurelium Biopharma, Inc.Inventors: Elias Georges, Lucile Serfass, Anne-Marie Bonneau, Frédéric Dallaire
-
Patent number: 7666415Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.Type: GrantFiled: June 9, 2009Date of Patent: February 23, 2010Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
-
Patent number: 7666412Abstract: The present invention relates to methods for the diagnosis, evaluation and treatment of metastatic diseases using metastatic sequences, such as caveolin, to target metastatic cells. According to the methods of the present invention, certain cancers, including metastatic prostate cancer, may be treated by therapies which suppress expression of the caveolin gene. The present invention relates to biological technologies designed to block the activity of caveolin or the function of caveolae, including vector delivery of antisense caveolin sequences, the use of anti-caveolin antibodies, the use of promoters, and other approaches targeting the expression of caveolin.Type: GrantFiled: October 22, 2003Date of Patent: February 23, 2010Assignee: Baylor College of MedicineInventor: Timothy C. Thompson
-
Patent number: 7667021Abstract: The present invention includes isolated nucleic acids encoding fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). Also included are methods of using and producing the antibodies of the invention.Type: GrantFiled: November 13, 2006Date of Patent: February 23, 2010Assignee: Schering CorporationInventors: Yan Wang, Robert Greenberg, Leonard Presta, Jonathan A. Pachter, Judith Hailey, Peter Brams, Denise Williams, Mohan Srinivasan, Diane Feingersh
-
Patent number: 7662383Abstract: The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs are obtained by inserting the hypervariable regions (complementarity determining regions=CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.Type: GrantFiled: February 7, 2008Date of Patent: February 16, 2010Assignee: Aventis Pharma Deutschland GmbHInventors: Klaus Bosslet, Gerhard Seemann, Hans Harald Sedlacek, Bernhard Auerbach
-
Patent number: 7658924Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.Type: GrantFiled: November 4, 2004Date of Patent: February 9, 2010Assignee: Amgen Inc.Inventors: Jonathan Oliner, Kevin Graham
-
Patent number: 7655234Abstract: A gene (designated 161P2F10B) and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit a humoral or cellular immune response.Type: GrantFiled: April 1, 2005Date of Patent: February 2, 2010Assignee: Agensys, Inc.Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Karen Jane Meyrick Morrison, Aya Jakobovits
-
Patent number: 7651678Abstract: Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Interleukin-3 receptor alpha chain (IL-3R? or CD123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hematologic cancer (e.g., leukemia and lymphomic) cells by selectively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and malignant lymphoproliferative disorders. Also provided are compounds useful for selectively binding to CD123 and impairing progenitor hematologic cancer cells. These compounds may include cytotoxic moieites such as, for example, radioisotopes or chemotherapeutics.Type: GrantFiled: April 23, 2004Date of Patent: January 26, 2010Assignee: University of Kentucky Research FoundationInventor: Craig Jordan
-
Patent number: 7648703Abstract: A combination of an anti-Ep-CAM antibody with a chemotherapeutic agent that is capable of arresting Ep-CAM antigen expressing cells in S or G2/M.Type: GrantFiled: January 13, 2005Date of Patent: January 19, 2010Assignee: GlaxoSmithKline LLCInventors: Vincent C. Knick, Julie Beth Stimmel, Linda M. Thurmond
-
Patent number: 7641901Abstract: Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies.Type: GrantFiled: September 12, 2005Date of Patent: January 5, 2010Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Hans J. Hansen
-
Patent number: 7638605Abstract: This invention relates to human antibodies that bind to human insulin-like growth factor-1 receptor (IGF-IR), to derivatives of these antibodies (Fabs, single chain antibodies, bi-specific antibodes, or fusion proteins), and to uses of the antibodies and derivatives in therapeutic, and diagnostic methods. The invention relates to nucleic acids encoding the anti-IGF-IR, methods of generating the antibodies and expression. The invention further relates to combination therapies using ant-IGF-IR antibodies with anti-neoplastic drugs.Type: GrantFiled: May 3, 2004Date of Patent: December 29, 2009Assignee: ImClone, LLCInventor: Dale L. Ludwig
-
Patent number: 7635475Abstract: The purpose of the present invention is to provide a diabody-type bispecific antibody, which is characterized by having low immunogenicity and high infiltrating activity into tumor tissues, and by being easily mass-produced at a low cost with use of microorganisms, and by being easily altered in function by means of genetic engineering. The diabody-type bispecific antibody shows a more remarkable effect than the conventional diabody-type bispecific antibodies and chemically synthesized bispecific antibodies even in a very low concentration and in the absence of the super antigen.Type: GrantFiled: August 18, 2003Date of Patent: December 22, 2009Assignee: Tohoku Techno Arch Co., Ltd.Inventors: Izumi Kumagai, Toshio Kudo, Kouhei Tsumoto, Ryutaro Asano
-
Publication number: 20090304689Abstract: Methods and compositions for the development of effective cancer therapies using mitotic inhibitors which have limited general toxicity to normal, non-cancerous cells and tissues are provided. The methods and compositions utilize cytotoxic compounds comprised of a cell-binding agent (e.g., antibodies) conjugated to an anti-mitotic compound (e.g., maytansinoids). The invention further provides antibodies which are substantially incapable of inducing antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC), thereby ensuring that the therapeutic effect is mediated primarily by the anti-mitotic component of the cytotoxic compound, rather than by indirect cell killing via ADCC and/or CDC. The antibodies of the invention further are capable of differentiating between polypeptide antigens which are more highly expressed on proliferating cancer cells as compared to proliferating non-cancer cells.Type: ApplicationFiled: February 2, 2009Publication date: December 10, 2009Inventor: Arthur D. Levinson
-
Patent number: 7622118Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.Type: GrantFiled: August 15, 2003Date of Patent: November 24, 2009Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Sophia Ran
-
Patent number: 7622115Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.Type: GrantFiled: June 14, 2007Date of Patent: November 24, 2009Assignee: Genentech, Inc.Inventors: Gwendolyn Fyfe, Eric Holmgren, Robert D. Mass, William Novotny
-
Patent number: 7618631Abstract: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and EGFR-targeted drugs.Type: GrantFiled: June 16, 2005Date of Patent: November 17, 2009Assignee: Genentech, Inc.Inventor: Mark Sliwkowski
-
Patent number: 7619068Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.Type: GrantFiled: May 10, 2004Date of Patent: November 17, 2009Assignee: diaDexus, Inc.Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Jackie Papkoff
-
Patent number: 7615221Abstract: The invention features compositions and methods for treating or alleviating a symptom of cancer. The compositions and methods of the invention direct supra-lethal doses of radiation, called Hot-Spots, to virtually all cancer cell types.Type: GrantFiled: July 23, 2004Date of Patent: November 10, 2009Assignee: Oncologic, Inc.Inventors: George L. Mayers, David Lee, Hsiao-Ling Chin
-
Patent number: 7615216Abstract: Antibodies that specifically bind to CCR5 are useful for treating immunosuppressive disease.Type: GrantFiled: March 31, 2006Date of Patent: November 10, 2009Assignee: Roche Palo Alto LLCInventors: Michael Brandt, Surya Sankuratri, Ralf Schumacher, Stefan Seeber
-
Publication number: 20090274620Abstract: This invention relates to a hybridoma cell line which is capable of producing the monoclonal antibody G250.Type: ApplicationFiled: December 23, 2008Publication date: November 5, 2009Applicant: Wilex AGInventors: Egbert OOSTERWIJK, Sven WARNAAR, Stefan ULLRICH
-
Patent number: 7611706Abstract: The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.Type: GrantFiled: October 30, 2007Date of Patent: November 3, 2009Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas Schneider
-
Patent number: 7611708Abstract: Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.Type: GrantFiled: October 6, 2008Date of Patent: November 3, 2009Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Keting Chu, Lorianne K. Masuoka
-
Patent number: 7608269Abstract: An alternative HER-2/neu product, herstatin, consists of subdomains I and II from the ectodomain of p185HER-2 and a unique 79 amino acid C-terminus encoded by intron 8. Recombinant herstatin added to cells was found to bind to and inhibit p185HER-2. The effects of ectopic expression of herstatin in combination with either p185HER-2 or with its homolog, the EGF receptor, in several cell lines was studied. Cotransfection of herstatin with HER-2 inhibited p185HER-2 levels and caused an approximate 8-fold reduction in p185 tyrosine phosphorylation. Inhibition of p185HER-2 tyrosine phosphorylation corresponded to a dramatic decline in colony formation by cells that coexpressed p185HER-2 and herstatin. Herstatin also interferred with EGF activation of the EGF receptor in cotransfected cells as demonstrated by impaired receptor tyrosine phosphorylation, reduced receptor down-regulation, and growth suppression.Type: GrantFiled: August 14, 2001Date of Patent: October 27, 2009Assignee: Oregon Health and Science UniversityInventor: Gail M. Clinton
-
Patent number: 7608263Abstract: The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.Type: GrantFiled: October 30, 2007Date of Patent: October 27, 2009Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas Schneider
-
Patent number: 7601349Abstract: The present invention provides isolated GPBP-interacting 90 and 130 kDa polypeptides, and portions thereof (GIP90/130 polypeptides), antibodies to the GIP90/130 polypeptides, and pharmaceutical compositions thereof. The present invention also provides isolated GIP90/130 nucleic acid sequences, expression vectors comprising the nucleic acid sequences, and host cells transfected with the expression vectors. The invention further provides methods for detecting the GIP90/130 polypeptides or nucleic acid sequences, methods for inhibiting interactions between GPBP and GIP90/130 polypeptides, between pol k76 and GIP90/130 polypeptides or aggregation of GIP90/130 polypeptides, and methods for treating patients with autoimmune disorders or cancer.Type: GrantFiled: November 9, 2006Date of Patent: October 13, 2009Inventors: Juan Saus, Francisco Revert-Ros
-
Publication number: 20090246206Abstract: Methods for improving the specific binding ability of bispecific binding compositions are described. The bispecific binding compositions are able to target cells by a high affinity targeting domain to a target cell surface marker and a low affinity binding domain that binds specifically to a second cell surface marker, wherein the binding of each domain to its respective cell surface marker increases or decreases, as desired, the biological activity of the respective cell surface markers. The invention further provides bispecific binding agents for use in the methods, as well as uses for the agents.Type: ApplicationFiled: May 5, 2005Publication date: October 1, 2009Applicant: Merrimack Pharmaceuticals, Inc.Inventors: Ulrik B. Nielsen, Birgit M. Schoeberl
-
Patent number: 7595047Abstract: Compounds, compositions and methods for promoting or inhibiting angiogenesis, and screening methods for identifying compounds are disclosed. The compounds bind to F1 ATP synthase particularly to the alpha and/or beta subunits of F1 ATP synthase. When bound to these subunits, they can function as angiostatin agonists, antagonists, partial agonists, inverse agonists, or allosteric modulators. When the compounds mimic or enhance the activity of angiostatin, they inhibit angiogenesis. When the compounds inhibit the ability of angiostatin to bind F1 ATP synthase and are either inactive at inhibiting angiogenesis or directly promote angiogenesis, or if they inhibit the activity of angiostatin, they promote angiogenesis. The compounds can be, for example, antibodies, antibody fragments, enzymes, peptides, nucleic acids such as oligonucleotides, or small molecules. The antibodies can be monoclonal, humanized, or polyclonal antibodies.Type: GrantFiled: April 13, 2006Date of Patent: September 29, 2009Assignees: Duke University, Northwestern UniversityInventors: Tammy L. Moser, Salvatore V. Pizzo, Mary S. Stack
-
Patent number: 7589181Abstract: Humanized anti-TAG-72 CC49 monoclonal antibodies are disclosed herein. The antibodies include a light chain Complementarity Determining Region (L-CDR)1, a L-CDR2, and a L-CDR3; and a heavy chain Complementarity Determining Region (H-CDR)1, a H-CDR2, and a H-CDR3 from humanized antibody HuCC49V10. The L-CDR1, L-CDR2, L-CDR3 are within a HuCC49V10 light chain framework region that includes the corresponding amino acid from LEN at position 5, 19, 21, and 106 in the light chain. The H-CDR1, H-CDR2, and H-CDR3 are within a heavy chain HuCC49V10 framework comprising a human 21/28? CL residue at positions 20, 38, 48, 66, 67, 69, and 80 in the heavy chain. These humanized CC49 antibodies retain binding affinity for TAG-72 and have reduced immunogenicity, as compared to a parental HuCC49V10 antibody. Methods are disclosed herein for using these antibodies in the treatment or diagnosis of a tumor, such as a carcinoma, expressing TAG-72.Type: GrantFiled: August 27, 2004Date of Patent: September 15, 2009Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Syed V. S. Kashmiri, Jeffrey Schlom, Eduardo A. Padlan
-
Patent number: 7585505Abstract: A gene (designated 161P2F10B) and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit a humoral or cellular immune response.Type: GrantFiled: April 1, 2005Date of Patent: September 8, 2009Assignee: Agensys, Inc.Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Karen Jane Meyrick Morrison, Aya Jakobovits
-
Patent number: 7585953Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: September 13, 2005Date of Patent: September 8, 2009Assignee: Genentech, Inc.Inventors: Ruihuan Chen, Heidi S. Phillips, P. Mickey Williams, Thomas Wu, Zemin Zhang
-
Patent number: 7582299Abstract: The invention provides Cripto-specific antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and inhibit Cripto activity are provided. Antibodies which bind Cripto and inhibit the interaction between Cripto and ALK4 and/or between Cripto and Activin B are provided. Antibodies which bind Cripto and inhibit tumor growth are also provided. Antibodies which bind Cripto, inhibit Cripto activity, and inhibit tumor growth are also provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications.Type: GrantFiled: September 20, 2004Date of Patent: September 1, 2009Assignee: Biogen Idec MA Inc.Inventors: Michele Sanicola-Nadel, Heather Adkins, Steven Donald Miklasz, Paul Rayhorn, Susan Gail Schiffer, Kevin P. Williams